

1 **Social determinants of injection drug use-associated bacterial infections and**  
2 **treatment outcomes: systematic review and meta-analysis**

3

4 Thomas D. Brothers<sup>1,2</sup>; Dan Lewer<sup>1,3</sup>; Matthew Bonn<sup>4,5</sup>; Inhwa Kim<sup>6</sup>; Emilie Comeau<sup>6</sup>; Mary Figgatt<sup>7,8</sup>;  
5 William Eger<sup>9</sup>; Duncan Webster<sup>2,10</sup>; Andrew Hayward<sup>1,11</sup>; Magdalena Harris<sup>12</sup>

6

7 <sup>1</sup>UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology & Health Care, University  
8 College London (UCL), London, UK

9 <sup>2</sup>Department of Medicine, Dalhousie University, Halifax, Canada

10 <sup>3</sup>Bradford Centre for Health Data Science, Bradford Institute for Health Research, Bradford, UK

11 <sup>4</sup>Canadian Association of People who Use Drugs (CAPUD), Dartmouth, Canada

12 <sup>5</sup>Canadian AIDS Society, Ottawa, Canada

13 <sup>6</sup>Dalhousie Medical School, Dalhousie University, Halifax, Canada

14 <sup>7</sup>Department of Epidemiology, University of North Carolina, Chapel Hill, USA

15 <sup>8</sup>Center for AIDS Research, University of Alabama at Birmingham, Birmingham, USA

16 <sup>9</sup>Joint Doctoral Program in Interdisciplinary Research on Substance Use, University of California – San  
17 Diego and San Diego State University, San Diego, USA

18 <sup>10</sup>Division of Infectious Diseases, Saint John Regional Hospital, Saint John, Canada

19 <sup>11</sup>Health Equity and Clinical Governance Division, UK Health Security Agency, London, UK

20 <sup>12</sup>Department of Public Health, Environments and Society, London School of Hygiene and Tropical  
21 Medicine (LSHTM), London, UK

22

23 **Address correspondence to:** [thomas.brothers.20@ucl.ac.uk](mailto:thomas.brothers.20@ucl.ac.uk) or [thomas.brothers@dal.ca](mailto:thomas.brothers@dal.ca) (TDB)

24

25 **ABSTRACT**

26 **Background:** Individual injecting practices (e.g., intramuscular injecting, lack of skin cleaning) are  
27 known risk factors for injection drug use-associated bacterial and fungal infections; however, social  
28 contexts shape individual behaviours and health outcomes. We sought to synthesize studies  
29 assessing potential social determinants of injecting-related infections and treatment outcomes.

30 **Methods:** We searched five databases for studies published between 1 January 2000 and 18  
31 February 18 2021 (PROSPERO CRD42021231411). We included studies of association (aetiology),  
32 assessing social determinants, substance use, and health services exposures influencing  
33 development of injecting-related infections and treatment outcomes. We pooled effect estimates  
34 via random effects meta-analyses.

35 **Results:** We screened 4,841 abstracts and included 107 studies. Several factors were associated with  
36 incident or prevalent injecting-related infections: woman/female gender/sex (adjusted odds ratio  
37 [aOR] 1.57, 95% confidence interval [CI] 1.36-1.83; n=20 studies), homelessness (aOR 1.29, 95%CI  
38 1.16-1.45; n=13 studies), cocaine use (aOR 1.31, 95%CI 1.02–1.69; n=10 studies), amphetamine use  
39 (aOR 1.74, 95%CI 1.39-2.23; n=2 studies), public injecting (aOR 1.40, 95%CI 1.05–1.88; n=2 studies),  
40 requiring injecting assistance (aOR 1.78, 95%CI 1.40–2.27; n=8 studies), and use of opioid agonist  
41 treatment (aOR 0.92, 95%CI 0.89–0.95; n=9 studies). Studies assessing outcomes during treatment  
42 (e.g., premature hospital discharge) or afterward (e.g., rehospitalization; all-cause mortality)  
43 typically had smaller sample sizes and imprecise effect estimates.

44 **Conclusions:** Injecting-related infections and treatment outcomes may be shaped by multiple social  
45 contextual factors. Approaches to prevention and treatment should look beyond individual injecting  
46 practices towards addressing the social and material conditions within which people live, acquire  
47 and consume drugs, and access health care.

## 48 INTRODUCTION

49 Injecting-related bacterial and fungal infections cause significant morbidity and mortality among  
50 people who inject drugs, with 6-32% of people reporting an infection in the past month and up to  
51 64% reporting a skin and soft-tissue infection (SSTI) in the past year.<sup>1</sup> Incidence of these infections is  
52 increasing in North America, Europe, and Australia.<sup>2-5</sup> Specific drug preparation and injecting  
53 practices (including subcutaneous or intramuscular injecting, reusing blunted or contaminated  
54 needles and syringes, and not sterilizing skin before injecting) are known risk factors.<sup>1,6</sup> Individual-  
55 level educational interventions have been developed to promote safer drug injecting techniques, but  
56 these have shown inconsistent efficacy.<sup>7-9</sup> Individual-level interventions may have limited impact  
57 because drug injecting practices are shaped by social contexts and material resources.<sup>10</sup> For  
58 example, people without secure housing are more likely to inject in public or unhygienic spaces (e.g.,  
59 abandoned buildings).<sup>10,11</sup> People with insufficient access to needle and syringe programs may need  
60 to reuse contaminated equipment.<sup>10,12,13</sup>

61 Treatment of injection drug use-associated bacterial and fungal infections is also often  
62 suboptimal.<sup>10,14-16</sup> People who inject drugs describe negative experiences of untreated pain and  
63 withdrawal in health care settings, which discourages access to care.<sup>10,17-19</sup> Clinicians caring for  
64 people with injecting-related infections describe not knowing how best to help.<sup>16,20</sup> Poor care  
65 experiences and outcomes are also affected by social determinants and system-level factors.<sup>10,14,21,22</sup>  
66 Most acute care hospitals do not integrate substance use and addiction care, and many hospitals  
67 have abstinence-based policies that lead patients to surreptitiously use drugs (e.g., in locked  
68 bathrooms) or leave the hospital prematurely.<sup>16,22-27</sup> As a result, risk of fatal opioid overdose is two  
69 to four times higher in the days after hospital discharge compared to other times,<sup>27,28</sup> and  
70 rehospitalizations with recurrent injecting-related infections are common.<sup>29,30</sup>

71 Prevention and treatment strategies for injecting-related infections may be greatly improved if  
72 clinicians and health systems look more broadly to the social and structural factors that shape  
73 individual injecting practices and treatment outcomes. Such approaches have informed prevention  
74 and treatment strategies for HIV<sup>31-34</sup> and hepatitis C virus<sup>32,35</sup>, and prevention strategies for opioid  
75 overdose<sup>33,36</sup>, but less is known about how social determinants influence injecting-related bacterial  
76 and fungal infections.<sup>10,37</sup>

77 To better understand and quantify the influence of social determinants on injecting-related  
78 infections and treatment outcomes (and to identify opportunities for novel interventions to improve

79 prevention and treatment), we sought to systematically review and meta-analyse the quantitative  
80 literature on this topic. This review seeks to answer the question, “Among people who inject drugs,  
81 what social and structural factors influence the development of, treatment of, and outcomes of  
82 injecting-related bacterial and fungal infections?”

## 83 **METHODS**

84 We registered (PROSPERO CRD42021231411) and published a protocol<sup>37</sup> and before conducting the  
85 search. We modified the protocol after full-text review. The protocol specified a “mixed studies”  
86 review of quantitative, qualitative, and mixed-methods sources.<sup>38</sup> As we identified more studies than  
87 anticipated, we separately reviewed and synthesized quantitative and qualitative studies. Here, we  
88 report the quantitative systematic review and meta-analyses. Qualitative results are reported  
89 elsewhere.<sup>10</sup> Our approach is informed by the Conducting Systematic Reviews and Meta-Analyses of  
90 Observational Studies of Etiology (COSMOS-E)<sup>39</sup> guidance. We followed Preferred Reporting Items  
91 for Systematic reviews and Meta-Analyses (PRISMA) reporting guidelines.<sup>40</sup>

### 92 **Eligibility criteria**

93 Eligibility criteria are detailed in the protocol.<sup>37</sup> Briefly, we included quantitative studies of  
94 association (aetiology),<sup>39,41</sup> published in peer-reviewed journals. We followed the Population,  
95 Exposures, Outcomes approach.<sup>41</sup> “Participants” were people who inject psychoactive substances.  
96 “Exposures” were social or environmental factors that could affect risk for developing infections or  
97 influence their treatment. This includes social, economic, and political factors such as housing,  
98 income, drug policies, and other socially-patterned exposures such as availability of (or use of)  
99 different substances, harm reduction services, drug treatment, and health care. Informed by a socio-  
100 ecological model (the “intersectional risk environment”<sup>33,34</sup>), we also considered socially-constructed  
101 identities and locations within social power hierarchies, including by gender/sex and race/ethnicity.<sup>33</sup>  
102 While some sociodemographic characteristics (like gender, sex, or age) may confer effects through  
103 both biological and social-structural pathways, these are often interlinked and we expected that  
104 quantitative studies would not attempt to isolate purported biological-only effects.<sup>33,36</sup> Potential  
105 differences by gender/sex may reflect structural sexism, and potential differences by race/ethnicity  
106 may reflect structural racism.<sup>33,36,42</sup> “Outcomes” were injecting-related bacterial or fungal infections  
107 (and any reported outcomes during and after treatment of these infections), including SSTI (abscess,  
108 cellulitis, necrotizing fasciitis), sepsis or bacteraemia, vascular infections (endocarditis, septic  
109 phlebitis), bone and joint infections (osteomyelitis, septic arthritis, discitis), and central nervous

110 system infections (epidural abscess, brain abscess, meningitis, encephalitis). We included studies  
111 published between 1 January 2000 and 18 February 2021, in English or French.

## 112 **Information sources, search strategy, and data management**

113 We searched PubMed, EMBASE, Scopus, CINAHL, and PsycINFO databases. We supplemented this  
114 with forward and backward citation chaining and included articles from the review team's personal  
115 files. We developed the final search strategy in consultation with a health sciences librarian  
116 (Appendix 1).

117 Search results were uploaded into Covidence and automatically de-duplicated. Two reviewers (TDB  
118 and either MB, EC, IK, or DL) screened abstracts against the inclusion criteria, resolving discrepancies  
119 through consensus. TDB assessed full-text reports for inclusion and recorded reasons for exclusion.

## 120 **Data collection**

121 We developed and pilot-tested a data extraction form for studies with quantitative data. Data was  
122 extracted by TDB and checked independently by WE or MF. We extracted data on:

- 123 • First author and publication year
- 124 • Social and structural exposures included in the review
- 125 • Main exposure or estimand of the study (and whether all exposures assessed in our review  
126 reflect the study estimand)
- 127 • Infection types (e.g., SSTI, endocarditis, osteomyelitis, etc.)
- 128 • Infection-related outcomes
- 129 • Country (city) where study took place
- 130 • Sample size
- 131 • Sampling method (and parent study name, if applicable)
- 132 • Data collection period
- 133 • Inclusion criteria
- 134 • Proportion of sample that are women/female
- 135 • Age of sample
- 136 • Drugs used by  $\geq 50\%$  of the sample

137

138 As suggested in COSMOS-E guidance<sup>39</sup>, we manually extracted both unadjusted and fully covariate-  
139 adjusted effect estimates (with 95% confidence intervals), wherever possible. Following Kaufman<sup>43</sup>,

140 we conceptualized unadjusted analyses as associative (e.g., “are people experiencing homelessness  
141 more likely to have injecting-related infections?”) and covariate-adjusted effect estimates as  
142 attempting to identify causal relationships (aetiology; e.g., “does homelessness contribute to  
143 injecting-related infections?”).

144 Where summary effect estimates (e.g., odds ratios) were not reported, we extracted frequencies to  
145 calculate unadjusted odds ratios and standard errors. When studies reported only stratified analyses  
146 (e.g., separate effect estimates among women and men) we kept both effect estimates for meta-  
147 analyses. When studies reported highly related effect estimates (e.g., for measures of both  
148 “lifetime” and “past six months” homelessness) from the same sample, we included only one in  
149 meta-analysis to avoid double-counting and documented reasons for inclusion or exclusion.<sup>44</sup>  
150 Specifically, we selected the exposure-outcome pair with the most congruent timelines (e.g., “past  
151 six months” for exposure and outcome). As most studies reported effect estimates in odds ratios, we  
152 treated all relative effect estimates (including hazard ratios and rate ratios) as if they were odds  
153 ratios for meta-analysis.<sup>39</sup> When studies did not report statistics for null or nonsignificant findings,  
154 (instead reporting, e.g., “no associations found”), we recorded where this was reported but we could  
155 not include these in meta-analyses.

## 156 **Critical appraisal**

157 We applied the Mixed Methods Appraisal Tool<sup>45</sup> (MMAT; which is designed for use with quantitative,  
158 qualitative, and mixed-methods studies), following the “user guide”.<sup>46</sup> We included all studies which  
159 met both screening questions: “Are there clear research questions?” and “Do the collected data  
160 allow to address the research questions?”. For quantitative studies of association (aetiology), five  
161 criteria questions focus on whether the sample is representative of the target population, potential  
162 measurement error, if confounders are accounted for, and whether the exposure occurred as  
163 intended. The MMAT is scored only once per study, but many studies contain multiple exposure-  
164 outcome analyses that might have differing risks of bias. We scored a question as “No” if any  
165 exposure-outcome analysis in the study did not meet the criteria (e.g., if the timeline of exposure  
166 and outcome ascertainment did not align for one of many exposures assessed). Also, the MMAT only  
167 asks whether confounders were considered, not how they were selected or if they are appropriate.  
168 We scored “Yes” for studies that included covariate-adjusted analyses, no matter how covariates  
169 were selected. We assigned each study a score out of 5, by summing the questions answered “Yes”.  
170 We report MMAT scores for each study but did not otherwise use critical appraisal in syntheses.

## 171 **Meta-analyses**


172 We conducted separate inverse variance meta-analyses for each exposure-outcome pair in *R*  
173 (version 4.2.2), using the *meta* package.<sup>44</sup> We performed random-effects meta-analyses because we  
174 assumed there would be between-study heterogeneity (including different exposure and outcome  
175 definitions, study settings, and sampling frames).<sup>39</sup> We applied the DerSimonian-Laird estimator for  
176  $\tau^2$ ,<sup>47</sup> with the Knapp-Harding adjustment (which assumes a t-distribution of the standard error of the  
177 pooled effect size and reduces the chance of false positives).<sup>48</sup> We measured the percentage of total  
178 statistical variability attributable to between-study heterogeneity using  $I^2$  statistics.<sup>49</sup> We identified  
179 individual effect estimates as outliers if its confidence interval did not overlap with the confidence  
180 interval of the pooled effects (i.e., the effect size of the outlier is so extreme that it differs  
181 significantly from the meta-analysis summary effect).<sup>50</sup>

## 182 **RESULTS**

### 183 **Summary of included studies**

184 The mixed-studies search identified 8,167 references; after de-duplication, we screened 4,841  
185 abstracts and 631 full-text reports. We reviewed 16 additional full-text reports identified outside the  
186 search (Appendix 2). We excluded four quantitative studies because they failed the MMAT screening  
187 questions (Appendix 3).

188 We finally included 107 studies (Figure 1). There were 60 studies assessing incident or prevalent  
189 infections; 26 studies assessing outcomes during treatment (e.g., in-hospital mortality, premature  
190 hospital discharge); 29 studies assessing outcomes after treatment (e.g., infection-related  
191 rehospitalization, all-cause mortality); and five studies assessing colonisation with pathogenic  
192 bacteria.



193  
194

Figure 1. PRISMA 2020 flow diagram of included studies in quantitative systematic review of injecting-related infections

195 See Table 1 for summary of included studies and Appendices 4-7 for detailed characteristics of each  
 196 study. Two studies incorporated fungal infections (fungaemia and endogenous endophthalmitis); the  
 197 remaining 105 studies focused only on bacterial infections. Among the 60 studies where the  
 198 outcome was incident or prevalent injecting-related infections, 83% (n=50) included SSTI and  
 199 samples were median 28.6% women/female. Among studies where the outcomes occurred during or  
 200 after infection treatment, most focused on endocarditis (73% and 86%, respectively) and  
 201 woman/female participants were more common (48.2% and 43.2%, respectively). Overall, most  
 202 studies were from North America, followed by Europe (especially the United Kingdom). Few studies  
 203 came from Asia (n=2) or Africa (n=1), and none from South America.

204 See Appendices 8-11 for full MMAT critical appraisal results. See Appendices 12-15 for all extracted  
 205 effect estimates and Appendix 16 for details of selecting and transforming effect estimates for  
 206 inclusion in meta-analyses.



207 Table 1. Summary of included studies in quantitative systematic review on injecting-related bacterial and fungal infections.

Characteristic	Level	Studies on incident or prevalent infections	Studies on outcomes during treatment for infection	Studies on outcomes after infection	Studies on colonization
Studies (n)		60 studies	26 studies	29 studies	5 studies
Sample sizes (no. of participants)	Median (range)	623 (45 – 60,529)	244 (20 – 605,859)	125 (19 – 27,432)	282 (78 – 497)
Age (mean or median), years	Median (range)	37 (27.5 – 47.1)	38 (25.8 – 47.2)	35.9 (28.5 – 46)	40.5 (38.7 – 47.6)
Gender/sex (% women/female)	Median (range)	28.6% (0.0% - 77%)	43.2% (2.9% - 69.0%)	48.2% (12.5% - 70%)	21.1% (16.0% - 41.0%)
Infection syndrome <sup>a</sup>	No. (%) of studies				
	Skin and soft-tissue infections	50 (83%)	13 (50%)	4 (14%)	-
	Endocarditis	14 (23%)	19 (73%)	25 (86%)	-
	Sepsis/bacteraemia	5 (8%)	6 (23%)	3 (10%)	-
	Osteomyelitis	4 (7%)	9 (35%)	7 (24%)	-
	Septic arthritis	3 (5%)	6 (23%)	4 (14%)	-
	Spinal epidural abscess	2 (3%)	2 (8%)	3 (10%)	-
	Other	Pneumonia: 1 (2%)	Fungemia: 2 (8%) Pneumonia: 1 (4%) Botulism: 1 (4%) Endophthalmitis: 1 (4%)	Endophthalmitis: 1 (3%)	S. aureus colonization: 2 (40%) Methicillin-resistant S. aureus (MRSA): 5 (100%)
	Not specified	3 (5%)	0	0	0
	Multiple	9 (15%)	9 (35%)	7 (24%)	2 (40%)
Country	No. (%) of studies				
	United States	25 (42%)	18 (69%)	18 (62%)	3 (60%)
	Canada	11 (18%)	3 (12%)	3 (10%)	0
	United Kingdom	12 (20%)	2 (8%)	1 (3%)	1 (20%)
	Australia	1 (2%)	0	2 (7%)	0
	France	1 (2%)	0	0	0
	Germany	1 (2%)	0	0	0
	India	1 (2%)	0	0	0
	Sweden	1 (2%)	0	1 (3%)	0
	Switzerland	1 (2%)	1 (4%)	0	1 (20%)

	Thailand	1 (2%)	0	0	0
	South Africa	0	1 (4%)	0	0
	Spain	0	1 (4%)	0	0
Publication year	No. (%) of studies				
	2018-2021	18 (30%)	15 (58%)	26 (90%)	2 (40%)
	2014-2017	16 (27%)	1 (4%)	2 (7%)	1 (20%)
	2010-2013	11 (18%)	4 (15%)	1 (3%)	1 (20%)
	2006-2009	8 (13%)	3 (12%)	0	1 (20%)
	2000-2005	7 (12%)	2 (8%)	0	0
No estimand or primary exposure not specified <sup>b</sup>	No. (%) of studies	30 (50%)	16 (62%)	11 (38%)	5 (100%)

<sup>a</sup>Total adds up to greater than 100% as several studies included more than one infection syndrome

<sup>b</sup>These are studies that did not aim to model a specific exposure or treatment effect as accurately as possible, but rather aimed to identify “factors associated with” an outcome. They either tested several unadjusted analyses (e.g., in case-control study) or tested multiple exposures at once in multivariable regression (e.g., stepwise regression, without a hypothesis or main exposure).

208 **Incident or prevalent injecting-related infections**


209 Sixty studies assessed factors associated with incident or prevalent injecting-related infections,  
210 including sociodemographic factors (gender/sex, age, race/ethnicity, education,  
211 income/employment, relationship status, migration), social and housing support characteristics  
212 (incarceration, sex work, unstable housing/homelessness, food insecurity, health insurance),  
213 substance use-related factors (overdose history, heroin use, heroin formulation [i.e., tar vs. powder],  
214 prescription-type opioids, cocaine [including crack and powder], amphetamines [including  
215 methamphetamines], prescription-type stimulants, novel psychoactive stimulants,  
216 speedball/goofball use, alcohol, smoking), drug policy and injecting contexts (drug policy changes,  
217 drug purchasing network, public injecting, use of shooting galleries, police contacts/arrests,  
218 requiring or receiving injecting assistance, injecting with others), and harm reduction and drug  
219 treatment (needle and syringe programs, opioid agonist treatment, supervised consumption sites).

220 See Figure 2 for a summary of exposures and associated meta-analytic effect estimates. See Figure 3  
221 for forest plots of unadjusted and adjusted effect estimates for three selected exposures:  
222 incarceration history, unstable housing or homelessness, and needle and syringe program use. See  
223 Appendix 17 for full results, including forest plots for each exposure.

224 Briefly, we identified evidence to support associations between several factors with incident or  
225 prevalent injecting-related infections, in meta-analyses of covariate-adjusted effect estimates:  
226 woman/female gender/sex (adjusted odds ratio [aOR] 1.57, 95% confidence interval [CI] 1.36-1.83;  $I^2$   
227 47%; n=20 studies), unstable housing and homelessness (aOR 1.29, 95%CI 1.16-1.45;  $I^2$  9%; n=13  
228 studies; Figure 3), cocaine use (aOR 1.31, 95%CI 1.02–1.69;  $I^2$  75%; n=10 studies), amphetamine use  
229 (aOR 1.74, 95%CI 1.39-2.23;  $I^2$  0%; n=2 studies), public injecting (aOR 1.40, 95%CI 1.05–1.88;  $I^2$  0%;  
230 n=2 studies), requiring/receiving injecting assistance (aOR 1.78, 95%CI 1.40–2.27;  $I^2$  48%; n=8  
231 studies), and use of opioid agonist treatment (aOR 0.92, 95%CI 0.89–0.95;  $I^2$  50%; n=9 studies). For  
232 several other exposures, we identified evidence to support an association only in meta-analyses of  
233 unadjusted (but not covariate-adjusted) effect estimates: lower income/unemployment (unadjusted  
234 odds ratio [uOR] 1.44, 95%CI 1.22-1.71;  $I^2$  79%; n=16 studies), incarceration history (uOR 1.27, 95%CI  
235 1.06-1.53;  $I^2$  81%; n=6 studies; Figure 3), sex work (uOR 1.49, 95%CI 1.06-2.09;  $I^2$  89%; n=8 studies),  
236 heroin use (uOR 1.35, 95%CI 1.13-1.61;  $I^2$  75%; n=20 studies), speedball (heroin and cocaine  
237 together) or goofball (heroin and methamphetamines together) use (uOR 1.34, 95%CI 1.15-1.57;  $I^2$   
238 51%; n=12 studies). For all other exposures (including needle and syringe program use, aOR 0.75,

It is made available under a [CC-BY 4.0 International license](#) .


239 95%CI 0.54-1.03; Figure 3), meta-analyses of unadjusted or covariate-adjusted effect estimates  
240 included null effect within their 95% confidence intervals.



241  
242  
243  
244

Figure 2. Summary of exposures and meta-analytic effect estimates among studies where outcome is incident or prevalent injecting-related bacterial infection. CI: confidence interval. See supplementary appendices for data on the remaining exposures (injecting prescription-type opioids; injecting other prescription-type stimulants, injecting novel psychoactive stimulants, smoking, drug policy changes, for drug-purchasing network) that could not be presented as single summary effect estimates.

245  
246



247  
248  
249

Figure 3. Forest plots for meta-analyses of selected exposures among studies where outcome is incident or prevalent injecting-related bacterial or fungal infections. In the panel on the left, the exposure is unstable housing or homelessness; in the panel on the top right, it is incarceration history; in the panel on the bottom right, the exposure is needle and syringe program use. CI: confidence interval. C&P: Care & Prevent cohort, UAM: Unlinked Anonymous Monitoring survey cohort (both reported in Doran 2020).

250 **Outcomes occurring during treatment for injecting-related infections**

251 We identified 26 studies assessing several outcomes during treatment/care of injecting-related bacterial  
 252 infections. See Table 2 for the eight outcomes and list of exposures assessed in relation to each.

253 *Table 2. Summary of outcomes and associated exposures assessed among studies where outcome occurs during treatment for*  
 254 *injecting-related infections.*

Outcomes	Exposures assessed	Number of studies
Health care-seeking for injecting-related infections	gender/sex; age; income/employment; sex work; unstable housing; incarceration; overdose history; migration status; heroin use; cocaine use; amphetamine use; opioid agonist treatment; supervised consumption site use	4
Self-treatment of abscess	gender/sex; age; race/ethnicity; unstable housing; heroin use; cocaine use; needle and syringe programs; several measures of access to health care (e.g., having a primary care provider or having health insurance)	2
Hospital admissions among people with an injecting-related SSTI	gender/sex; age; race/ethnicity; education; income/employment; sex work; migration status; unstable housing/homelessness; incarceration history; overdose history; heroin; cocaine; amphetamines; alcohol use; needle and syringe program use; access to health care (e.g., insurance, having a primary care provider); self-treatment of infections; hospital admission history	2
Premature hospital discharges, among people hospitalized with injecting-related infections	gender/sex; age; race/ethnicity; income/employment; unstable housing; overdose history; opioid use; cocaine; alcohol; other substance use; health care access; opioid agonist treatment; in-hospital addiction treatment; hospital characteristics; hospital policy; surgery during hospitalization	10
New/secondary bloodstream infections among people receiving antibiotic treatment	gender/sex; age; unstable housing and homelessness; substance use (heroin, stimulants, polysubstance use, other); substance use treatment; insertion of peripherally-inserted intravenous central catheters (PICC lines) for parenteral antimicrobial treatment	1
In-hospital death	gender/sex; age; race/ethnicity; overdose history; substance use (opioids, stimulants); health care access (insurance); hospital policies; surgery during hospital admission	5
Development of endogenous endophthalmitis	gender/sex; race/ethnicity; alcohol use; infection of central venous catheter	1
Respiratory failure among people with botulism	gender/sex; age	1

255 Studies assessing outcomes during treatment for injecting-related infections typically had smaller  
 256 sample sizes and imprecise effect estimates (compared to studies assessing incident or prevalent

257 injecting-related infections) and findings were inconsistent between studies. Many exposures were only  
 258 assessed in one study, limiting meta-analyses.

259 See Appendix 18 for full results including several meta-analyses for studies in the section. Among  
 260 exposure-outcome pairs assessed in more than one study, we identified supporting evidence for only  
 261 one association. Lacking health insurance was associated with increased risk of premature hospital  
 262 discharge (aOR 2.07, 95%CI 1.09-3.91;  $I^2$  85%; n=4 studies), among people hospitalized with injecting-  
 263 related infections in one U.S. study. In other country settings (e.g., United Kingdom or Canada), universal  
 264 public health insurance covers hospital services.

### 265 **Outcomes occurring after initial treatment of injecting-related infection**

266 We identified 29 studies assessing outcomes after initial treatment for injecting-related infections. See  
 267 Table 3 for six outcomes, and which exposures were assessed in relation to each.

268 *Table 3. Summary of outcomes and associated exposures assessed among studies where outcome occurs after initial treatment*  
 269 *for injecting-related infections.*

Outcomes	Exposures assessed	Number of studies
Infection-related rehospitalization (after discharge from an initial hospital admission with injecting-related infections)	gender/sex; age; race/ethnicity; rural residency; substance use (injecting prescription opioids); opioid agonist treatment; other substance use treatment; hospital policy; premature hospital discharge against medical advice; cardiac surgery during admission	8
All-cause rehospitalization	gender/sex; age; race/ethnicity; unstable housing; access to healthcare (health insurance); substance use (heroin, cocaine, methamphetamine, other); opioid agonist treatment; other addiction treatment; hospital policies; antibiotic treatment models; surgery during hospital admission	9
Overdose-related rehospitalization	gender/sex; age; substance use; opioid agonist treatment; hospital policy	2
All-cause mortality	gender/sex; age; unstable housing; substance use (opioid, stimulant, polysubstance use); premature hospital discharge against medical advice; opioid agonist treatment; other addiction medicine treatment; hospital policy; surgery during hospital admission	14
Failure of outpatient parental antimicrobial therapy [OPAT]	age; discharge setting	3
Change in visual acuity following treatment for endogenous endophthalmitis	gender/sex; age	1



270 Studies assessing outcomes after treatment also typically had imprecise effect estimates and  
271 inconsistent findings between studies, and opportunities for meta-analyses were limited.

272 See Appendix 19 for full results including several meta-analyses amongst studies in this section. Only  
273 two exposure-outcome associations were found to be significant in meta-analyses incorporating more  
274 than one study. Woman/female gender/sex was associated with increased risk of all-cause  
275 rehospitalization. Summary meta-analysis of three covariate-adjusted effect estimates was aOR 1.22  
276 (95%CI 1.08-1.38;  $I^2$  0%). One unadjusted effect estimate was nonsignificant at uOR 1.23 (95%CI 0.77-  
277 1.96). Inpatient addiction medicine consultation (during hospitalization with injecting-related infections)  
278 was associated with reduced risk of all-cause rehospitalization; summary of two unadjusted effect  
279 estimates was uOR 0.46 (95%CI 0.33-0.63;  $I^2$  0%) and one fully-adjusted effect estimate was aOR 0.57  
280 (95%CI 0.38–0.86).

### 281 **Colonisation with pathogenic bacteria**

282 Five studies assessed factors associated with colonisation with *Staphylococcus aureus* or methicillin-  
283 resistant *S. aureus* among people who inject drugs: gender/sex; age; race/ethnicity; education;  
284 employment; relationship status; unstable housing and homelessness; incarceration; substance use  
285 (heroin, cocaine, crack, speedball, methamphetamines, prescription opioids; cannabis); public injecting;  
286 injecting in groups; opioid agonist treatment; other addiction treatment; recent hospital admission; and  
287 other (e.g. using public shower facilities). Several exposures had significant associations in single studies  
288 (e.g., public injecting, injecting frequently with three or more people, sleeping at more than one place  
289 during the prior week), but none were significant in meta-analyses of multiple studies. See Appendix 20  
290 for full results among studies on colonization.

## 291 **DISCUSSION**

292 In this systematic review and meta-analysis, we identified 107 studies that assessed social determinants,  
293 substance use, and health services factors in relation to injecting-related bacterial infections and  
294 treatment outcomes. Several individual-level injecting risk practices (i.e., intramuscular or subcutaneous  
295 injecting, more frequent injecting, and lack of skin cleaning) were already known to be risk factors for  
296 these infections,<sup>1</sup> and we were interested in the social contextual factors that can influence injecting  
297 practices and treatment experiences. In meta-analyses, we found evidence that risk for injecting-related

298 infections was increased with woman/female gender/sex, less education, a history of incarceration, sex  
299 work, unstable housing and homelessness, heroin use, cocaine use, public injecting, and requiring or  
300 receiving injecting assistance. Among harm reduction and drug treatment factors, opioid agonist  
301 treatment was associated with a modest reduction in risk (i.e., ~8% lower odds). Overall, there were  
302 many more studies where the outcome was incident or prevalent injecting-related infections than there  
303 were studies assessing health outcomes occurring during or after infection treatment (e.g., premature  
304 hospital discharge; all-cause mortality). Most studies that focused on outcomes occurring during or after  
305 infection treatment had small sample sizes and imprecise effect estimates, and most exposures assessed  
306 in this setting were only addressed in one study (so could not be meta-analysed). While this review  
307 incorporated a broad scope, there was insufficient evidence (with imprecise effect estimates) for many  
308 potential exposures, and interpreting meta-analyses was limited by high clinical and statistical  
309 heterogeneity. Nevertheless, the importance of social-structural factors on the risk of injecting-related  
310 infections and their treatment suggests that future approaches to improving prevention and treatment  
311 should look more broadly than individual-level injecting practices and engage with the social and  
312 material conditions within which people live, acquire drugs, consume them, and access health care.

313 The findings of this quantitative systematic review and meta-analysis complement a qualitative  
314 systematic review and thematic synthesis, published recently by our group.<sup>10</sup> In the qualitative review,  
315 we identified several potential mechanisms through which social-structural factors could influence risk  
316 for injecting-related infections and poor treatment outcomes, including unregulated drug quality (e.g.,  
317 poorly soluble drugs or adulterants contributing to skin and vein damage), insufficient housing (e.g.  
318 people not having access to running water to prepare drugs, or adequate lighting to find a vein),  
319 criminalization and enforcement (e.g., people compromising their drug preparation practices and  
320 rushing to inject their drugs intramuscularly to avoid police search and seizure), and operational  
321 limitations on harm reduction services (e.g. insufficient funding, or geographic restrictions). We also  
322 identified that harmful health care policies and practices lead to negative experiences of undertreated  
323 pain and withdrawal that discourage people from accessing care until infections had worsened and  
324 spread, or otherwise contribute to people leaving hospital prematurely against medical advice (before  
325 their treatment is complete). In the quantitative meta-analyses reported here, we identified consistent  
326 evidence of population-level effects for some of those exposures, but not for others. For example, here  
327 we identified evidence to support an association between incident or prevalent injecting-related  
328 infections with unstable housing or homelessness and injecting in public. A history of police contacts and

329 arrests may have been associated with risk for infections (aOR 1.19, 95%CI 0.61-2.31), with imprecise  
330 confidence intervals that could include meaningful differences. However, this is measuring a different  
331 phenomenon than a concurrent police encounter contributing to a specific abscess for an individual.

332 In the qualitative review, participants highlighted the key role of harm reduction programs, like  
333 sufficient needle and syringe program coverage and access to supervised consumption sites, in enabling  
334 their ability to reduce risks for infection. Here, we did not identify evidence to support risk reduction  
335 with use of needle and syringe programs (aOR 0.75, 95%CI 0.54-1.03) or supervised consumption sites  
336 (aOR 0.59, 95%CI 0.29-1.19). Pooled effect estimates were imprecise and may include clinically  
337 meaningful reductions (or increases) in risk. These statistics from (mostly) cross-sectional observational  
338 studies may also show that needle and syringe programs and supervised consumption sites are  
339 successfully engaging people at highest risk of bacterial infections. This same phenomenon was  
340 observed in early research on HIV infection among people accessing needle and syringe programs.<sup>51-53</sup> In  
341 addition, there were two ecological studies (that we could not include in meta-analyses) showing a  
342 reduction in injecting-related infections after people started accessing needle and syringe programs. A  
343 study published after our search found that people who regularly attended supervised consumption  
344 sites in France were less likely to report a recent abscess (18% vs. 22%).<sup>54</sup> We identified that use of  
345 opioid agonist treatment was associated with a modest reduction in risk for injecting-related infections  
346 (aOR 0.92, 95%CI 0.89-0.95). Three studies on opioid agonist treatment and incident injecting-related  
347 infections, published after our search, estimated similar effects.<sup>3,29,55</sup>

348 In the context of the social determinants of health (and the closely related concepts of structural  
349 vulnerability and structural violence), we were interested in social identities and locations within  
350 societal power hierarchies which may enable or constrain the ability of people who inject drugs to  
351 prevent injecting-related infections and/or access treatment.<sup>33,34</sup> We identified evidence to support  
352 associations between some sociodemographic characteristics and risks of injecting-related bacterial  
353 infections, including woman/female gender/sex, lower educational attainment, lower  
354 income/unemployment, incarceration, and sex work. We did not identify evidence to support  
355 associations with other characteristics, including by race/ethnicity. We conceptualized race as a proxy  
356 measure for the effects of structural racism<sup>42,43</sup>, and the absence of evidence identified here does not  
357 necessarily mean that racism is not an important determinant of injecting-related infections or  
358 treatment outcomes. While many studies considered sociodemographic characteristics as covariates in

359 regression models (e.g., 17 studies included effect estimates for race/ethnicity on incident/prevalent  
360 infections), few studies were designed specifically to model the effect of these exposures (e.g., only one  
361 study modelled race/ethnicity as a primary exposure). In studies that did not specify a main exposure or  
362 estimand (instead considering all available variables in stepwise regressions), the effect of “upstream”  
363 exposures (e.g., structural racism) may be inappropriately blocked or hidden by conditioning on  
364 potential mediating variables (e.g., income, employment, or housing status that may be patterned by  
365 structural racism).<sup>42,43</sup>

366 Women may face excess risks of bacterial infections in the context of gendered power dynamics, for  
367 example that would lead them to “go second” and reuse contaminated equipment when injecting with  
368 male partners.<sup>33,56,57</sup> Women may be less likely to know how to inject themselves, and more likely to rely  
369 on assisted-injecting (which could reduce risks of intramuscular injection and abscesses in some people,  
370 but was associated with increased risks of bacterial infections in this review).<sup>58,59</sup> Women may also be  
371 less likely to engage with harm reduction programs (which are more likely to have been designed for  
372 men); very few harm reduction programs (e.g., supervised consumption sites) are gender-attentive or  
373 gender-specific.<sup>33,60-62</sup> Some investigators have also hypothesized that excess risk of infections among  
374 women is attributable to deeper peripheral veins, due to different distributions of adipose tissue (and so  
375 women may have more difficulty accessing veins and may be more likely to inject in subcutaneous  
376 tissue).<sup>6</sup> These differing risks are reflected in the greater proportion of woman/females in studies during  
377 and after treatment of injecting-related infections compared to studies assessing risk of incident or  
378 prevalent infections. Fewer studies focused on outcomes during and after treatment, which led to  
379 inconsistent findings. For example, woman/female gender/sex appeared associated with higher risks of  
380 all-cause rehospitalization but not infection-related rehospitalization, and it is unclear why this would be  
381 the case.

382 We also found that several substances were associated with higher risks of injecting-related bacterial  
383 infections, this including frequent or any use (vs. less or no use) of injection heroin, cocaine, and  
384 amphetamines. Studies that compared “frequent” (typically “daily or more”) use to less use did not  
385 consistently find that more frequent use of these substances was associated with greater risks of  
386 infections. Several studies also assessed specific formulations of unregulated drugs. Use of tar heroin  
387 (compared to powder heroin) was associated with nearly eight-fold increased risk of injecting-related  
388 bacterial infections in a covariate-adjusted analysis in one study<sup>63</sup>, and two-fold increased risk in a

389 second (ecological) study.<sup>64</sup> This may be because tar heroin is less soluble (leading to more undissolved  
390 particulate matter that can damage veins) and also that tar heroin requires the addition of acidifiers to  
391 dissolve and prepare for injection (and overuse of acidifiers contributes to vein sclerosis).<sup>6,65,66</sup> “Crack”  
392 cocaine (base) formulations also require the addition of acidifiers to prepare the drug solution for  
393 injecting (while powder cocaine hydrochloride does not), but use of both crack and powder cocaine  
394 were associated with increased risks in meta-analyses of unadjusted analyses. Other specific substances  
395 were associated with increased risk of injecting-related infections in individual studies, including of  
396 ethylphenidate (a novel synthetic stimulant, associated with high frequency of injecting). In research  
397 external to this review, investigators have hypothesized that the North American drug supply transition  
398 to fentanyl has driven increasing incidence of injecting-related infections, as fentanyl has a shorter half-  
399 life than heroin and is associated with more frequent injecting.<sup>2,67,68</sup> We identified no studies directly  
400 assessing illicit fentanyl use and risks of infections; two studies published after our search found  
401 injecting-related infections to be more common among people who inject fentanyl.<sup>69,70</sup> Xylazine in the  
402 North American unregulated drug supply has also recently emerged as a cause of unusual wounds and  
403 infections; we identified no studies on xylazine here and we are not aware of any existing studies  
404 quantifying this risk.<sup>71,72</sup>

## 405 **Limitations**

406 This review has several important limitations. First, we only included studies where the outcomes were  
407 injecting-related infections or treatment outcomes, so we did not capture studies where the outcome  
408 was risky injecting practices (e.g., lack of skin cleaning) that are associated with infections.<sup>73-75</sup> Second,  
409 the inclusion of many exposures and outcomes (and, potentially, meta-analyses of unadjusted and  
410 covariate-adjusted effect estimates for each exposure) could lead to false positive findings through  
411 simply random chance (the so-called “multiple comparisons problem”). However, we wanted to take as  
412 broad a scope as possible to identify potential social determinants. Third, summary effect estimates  
413 from meta-analyses were likely not entirely accurate for several reasons: (a) we could not incorporate  
414 “negative” or “null” effect estimates from several studies that reported no statistics (only that the  
415 exposure and outcome were “not associated”) or reported unadjusted associations but dropped the  
416 variable in stepwise approaches to multivariable regression; (b) we combined effect estimates from  
417 studies with high heterogeneity (with different exposure and outcome definitions, timelines, sampling  
418 strategies, inclusion criteria, and study settings) which was often reflected in high measures of between-  
419 study statistical heterogeneity ( $I^2$  values); (c) most studies did not specify a hypothesis or estimand (and

420 most did not take a causal or prespecified approach to covariate selection), which meant that most  
421 estimates did not come from studies trying to model as accurate as an effect as possible. Fourth, the  
422 observational cohort, cross-sectional, and case-control studies included in this review rarely contributed  
423 to understanding of mechanisms by which specific exposures affect the risk of infections or other  
424 treatment outcomes. This is one of the strengths of the complementary qualitative review.<sup>10</sup> Future  
425 research focused on specific exposures and potential interventions could incorporate mixed-methods  
426 and critical realist methods to improve understanding of how these risks come about.<sup>38,51–53</sup> Fifth, our  
427 search did not include studies during the COVID-19 era, which may have changed the risk environment.  
428 For example, a study published after our search showed rapid decline in incidence of injecting-related  
429 infections coinciding with the implementation of COVID response measures in England, comprised of  
430 decreased social mixing and temporary private accommodations for all people sleeping outside and in  
431 congregate shelters (“Everyone In” initiative).<sup>5</sup>

## 432 **Conclusions**

433 Injecting-related infections, their treatment, and subsequent outcomes are shaped by multiple social  
434 determinants, substance use, and health services-related factors. Public health and clinical approaches  
435 to prevention and treatment should look more broadly than individual injecting practices, towards  
436 addressing the social and material conditions within which people live, acquire and consume drugs, and  
437 access health care.

438

## 439 **ACKNOWLEDGMENTS**

440 We acknowledge that T.D.B., M.B., E.C. and I.K. live and work in Mi'kma'ki, the ancestral and unceded  
441 territory of the Mi'kmaq, and D.W. lives and works in unsundered and unceded territory and  
442 traditional lands of Wolastoqiyik. This territory is covered by the Treaties of Peace and Friendship which  
443 the Mi'kmaq and Wolastoqiyik Peoples first signed with the British Crown in 1725. The treaties did not  
444 deal with surrender of lands and resources but, in fact, recognized Mi'kmaq and Wolastoqiyik title and  
445 established the rules for what was to be an ongoing relationship between nations. We are Treaty  
446 people.

447 We thank Louise Gillis (Research Data Librarian at Dalhousie University) for helpful feedback and  
448 assistance with our search strategy. We thank Ricky Bluthenthal (University of Southern California) and  
449 Joseph Hayes (University College London) for helpful feedback on earlier drafts. We thank authors who  
450 provided correspondence and/or further information about their studies: Kasha Bornstein, Dan  
451 Ciccarone, Samantha Colledge-Frisby, Irina Ianache, Alison Ivey, Lisa Maher, David Marsh, Kristen Morin,  
452 Viktor Mravčik, H  l  ne Peyi  re.

## 453 **FUNDING**

454 T.D.B. was supported by the Dalhousie University Internal Medicine Research Foundation Fellowship, a  
455 Canadian Institutes of Health Research Fellowship (CIHR-FRN# 171259) and through the Research in  
456 Addiction Medicine Scholars Program (National Institutes of Health/National Institute on Drug Abuse;  
457 R25DA033211). For part of this work he was supported by the Killam Postgraduate Scholarship, Ross  
458 Stewart Smith Memorial Fellowship in Medical Research and Clinician Investigator Program Graduate  
459 Stipend (all from Dalhousie University Faculty of Medicine). T.D.B. is also principal investigator for CIHR-  
460 FRN# 185469). M.B., E.C. and I.K. were supported in this work via the Ross Stewart Smith Memorial  
461 Fellowship in Medical Research (Principal Investigator: T.D.B.). D.L. was funded by a National Institute  
462 for Health Research Doctoral Research Fellowship (DRF-2018-11-ST2-016). M.H. was funded by a  
463 National Institute for Health Research Career Development Fellowship (CDF-2016-09-014). M.F. was  
464 funded by the National Institute of Drug Abuse (F31DA055345). The views expressed are those of the  
465 authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.  
466 These funders had no role in the conduct or reporting of the research.

467 **DECLARATION OF INTERESTS**

468 M.B. reports personal fees from AbbVie, a pharmaceutical research and development company, and  
469 grants and personal fees from Gilead Sciences, a research-based biopharmaceutical company, outside of  
470 the submitted work. The other authors report no competing interests.



## 471 REFERENCES

- 472 1. Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-  
473 related injury and disease among people who inject drugs. *Drug Alcohol Depend*. 2017 Feb  
474 1;171:39–49. <https://doi.org/10.1016/j.drugalcdep.2016.11.029>
- 475 2. Gomes T, Kitchen SA, Tailor L, Men S, Murray R, Bayoumi AM, et al. Trends in Hospitalizations for  
476 Serious Infections Among People With Opioid Use Disorder in Ontario, Canada. *Journal of*  
477 *Addiction Medicine*. 2022 Aug;16(4):433–9. <https://doi.org/10.1097/adm.0000000000000928>
- 478 3. Colledge-Frisby S, Jones N, Larney S, Peacock A, Lewer D, Brothers TD, et al. The impact of opioid  
479 agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent  
480 population: A retrospective data linkage study. *Drug and Alcohol Dependence*. 2022;236:109494.  
481 <https://doi.org/10.1016/j.drugalcdep.2022.109494>
- 482 4. See I, Gokhale RH, Geller A, Lovegrove M, Schranz A, Fleischauer A, et al. National Public Health  
483 Burden Estimates of Endocarditis and Skin and Soft-Tissue Infections Related to Injection Drug  
484 Use: A Review. *The Journal of Infectious Diseases*. 2020 Oct 1;222(Supplement\_5):S429–36.  
485 <https://doi.org/10.1093/infdis/jiaa149>
- 486 5. Lewer D, Brothers TD, Croxford S, Desai M, Emanuel E, Harris M, et al. Opioid injection-associated  
487 bacterial infections in England, 2002-2021: a time series analysis of seasonal variation and the  
488 impact of COVID-19. *Clinical Infectious Diseases*. 2023 Mar 14;ciad144.  
489 <https://doi.org/10.1093/cid/ciad144>
- 490 6. Robertson R, Broers B, Harris M. Injecting drug use, the skin and vasculature. *Addiction*. 2021  
491 Jul;116(7):add.15283. <https://doi.org/10.1111/add.15283>
- 492 7. Stein MD, Phillips KT, Herman DS, Keosaian J, Stewart C, Anderson BJ, et al. Skin-cleaning among  
493 hospitalized people who inject drugs: a randomized controlled trial. *Addiction*. 2021  
494 May;116(5):1122–30. <https://doi.org/10.1111/add.15236>
- 495 8. Phillips KT, Stewart C, Anderson BJ, Liebschutz JM, Herman DS, Stein MD. A randomized  
496 controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections among  
497 people who inject drugs. *Drug and Alcohol Dependence*. 2021 Feb 27;108646.  
498 <https://doi.org/10.1016/j.drugalcdep.2021.108646>
- 499 9. Roux P, Donadille C, Magen C, Schatz E, Stranz R, Curado A, et al. Implementation and evaluation  
500 of an educational intervention for safer injection in people who inject drugs in Europe: a multi-  
501 country mixed-methods study. *Int J Drug Policy*. 2021 Jan;87:102992.  
502 <https://doi.org/10.1016/j.drugpo.2020.102992>
- 503 10. Brothers TD, Bonn M, Lewer D, Comeau E, Kim I, Webster D, et al. Social and structural  
504 determinants of injection drug use-associated bacterial and fungal infections: a qualitative  
505 systematic review and thematic synthesis. *Addiction*. 2023 Oct;118(10):1853–77.  
506 <https://doi.org/10.1111/add.16257>

- 507 11. Harris RE, Richardson J, Frasso R, Anderson ED. Experiences with skin and soft tissue infections  
508 among people who inject drugs in Philadelphia: A qualitative study. *Drug and Alcohol*  
509 *Dependence*. 2018 Jun 1;187:8–12. <https://doi.org/10.1016/j.drugalcdep.2018.01.029>
- 510 12. Dunleavy K, Hope V, Roy K, Taylor A. The experiences of people who inject drugs of skin and soft  
511 tissue infections and harm reduction: A qualitative study. *Int J Drug Policy*. 2019;65:65–72.  
512 <https://doi.org/10.1016/j.drugpo.2018.09.001>
- 513 13. Harris M, Scott J, Hope V, Wright T, McGowan C, Ciccarone D. Navigating environmental  
514 constraints to injection preparation: the use of saliva and other alternatives to sterile water  
515 among unstably housed PWID in London. *Harm Reduct J*. 2020 Apr 10;17(1):24.  
516 <https://doi.org/10.1186/s12954-020-00369-0>
- 517 14. Brothers TD, Mosseler K, Kirkland S, Melanson P, Barrett L, Webster D. Unequal access to opioid  
518 agonist treatment and sterile injecting equipment among hospitalized patients with injection  
519 drug use-associated infective endocarditis. *PLoS ONE*. 2022 Jan 26;17(1):e0263156.  
520 <https://doi.org/10.1371/journal.pone.0263156>
- 521 15. Chan Carusone S, Guta A, Robinson S, Tan DH, Cooper C, O’Leary B, et al. “Maybe if I stop the  
522 drugs, then maybe they’d care?”—hospital care experiences of people who use drugs. *Harm*  
523 *Reduction Journal*. 2019 Feb 13;16(1):16. <https://doi.org/10.1186/s12954-019-0285-7>
- 524 16. Strike C, Robinson S, Guta A, Tan DH, O’Leary B, Cooper C, et al. Illicit drug use while admitted to  
525 hospital: Patient and health care provider perspectives. *PLOS ONE*. 2020 Mar 5;15(3):e0229713.  
526 <https://doi.org/10.1371/journal.pone.0229713>
- 527 17. Harris M. Normalised pain and severe health care delay among people who inject drugs in  
528 London: Adapting cultural safety principles to promote care. *Soc Sci Med*. 2020 Sep  
529 1;260:113183. <https://doi.org/10.1016/j.socscimed.2020.113183>
- 530 18. Gilbert AR, Hellman JL, Wilkes MS, Rees VW, Summers PJ. Self-care habits among people who  
531 inject drugs with skin and soft tissue infections: a qualitative analysis. *Harm Reduct J*. 2019 Dec  
532 12;16(1):69. <https://doi.org/10.1186/s12954-019-0345-z>
- 533 19. Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by  
534 people who inject drugs to avoid stigma in healthcare settings. *Drug and Alcohol Dependence*.  
535 2019 May 1;198:80–6. <https://doi.org/10.1016/j.drugalcdep.2019.01.037>
- 536 20. An KR, Luc JGY, Tam DY, Dagher O, Eikelboom R, Bierer J, et al. Infective endocarditis secondary  
537 to injection drug use: A survey of Canadian cardiac surgeons. *Ann Thorac Surg*. 2020 Dec 21;
- 538 21. McNeil R, Small W, Wood E, Kerr T. Hospitals as a “risk environment”: An ethno-epidemiological  
539 study of voluntary and involuntary discharge from hospital against medical advice among people  
540 who inject drugs. *Soc Sci Med*. 2014 Mar;105:59–66.  
541 <https://doi.org/10.1016/j.socscimed.2014.01.010>
- 542 22. Lennox R, Martin L, Brimner C, O’Shea T. Hospital policy as a harm reduction intervention for  
543 people who use drugs. *International Journal of Drug Policy*. 2021 Nov 1;97:103324.  
544 <https://doi.org/10.1016/j.drugpo.2021.103324>

- 545 23. Harris M, Holland A, Lewer D, Brown M, Eastwood N, Sutton G, et al. Barriers to management of  
546 opioid withdrawal in hospitals in England: a document analysis of hospital policies on the  
547 management of substance dependence. *BMC Medicine*. 2022 Apr 14;20(1):151.  
548 <https://doi.org/10.1186/s12916-022-02351-y>
- 549 24. Hyshka E, Morris H, Anderson-Baron J, Nixon L, Dong K, Salvalaggio G. Patient perspectives on a  
550 harm reduction-oriented addiction medicine consultation team implemented in a large acute  
551 care hospital. *Drug and Alcohol Depend*. 2019 Nov 1;204:107523.  
552 <https://doi.org/10.1016/j.drugalcdep.2019.06.025>
- 553 25. Brothers TD, Fraser J, MacAdam E, Hickcox S, L Genge, T O'Donnell, et al. Implementation and  
554 evaluation of a novel, unofficial, trainee-organized hospital addiction medicine consultation  
555 service. *Subst Abus*. 2021;42(4):433–7. <https://doi.org/10.1080/08897077.2020.1856291>
- 556 26. Barocas JA, Savinkina A, Adams J, Jawa R, Weinstein ZM, Samet JH, et al. Clinical impact, costs,  
557 and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a  
558 modelling study. *Lancet Public Health*. 2022 Jan;7(1):e56–64. [https://doi.org/10.1016/s2468-  
559 2667\(21\)00248-6](https://doi.org/10.1016/s2468-2667(21)00248-6)
- 560 27. Lewer D, Brothers TD, Harris M, Rock KL, Copeland CS. Opioid-related deaths during hospital  
561 admissions or shortly after discharge in the United Kingdom: A thematic framework analysis of  
562 coroner reports. *PLOS ONE*. 2023 Apr 19;18(4):e0283549.  
563 <https://doi.org/10.1371/journal.pone.0283549>
- 564 28. Lewer D, Eastwood B, White M, Brothers TD, McCusker M, Copeland C, et al. Fatal opioid  
565 overdoses during and shortly after hospital admissions in England: case-crossover study. *PLoS  
566 Med*. 2021 Oct 5;18(10):e1003759. <https://doi.org/10.1371/journal.pmed.1003759>
- 567 29. Brothers TD, Lewer D, Jones N, Colledge-Frisby S, Farrell M, Webster D, et al. Opioid agonist  
568 treatment and risk of death or rehospitalization following injection drug use-associated bacterial  
569 and fungal infections: a cohort study in New South Wales, Australia. *PLOS Medicine*.  
570 2022;19(7):e1004049. <https://doi.org/10.1371/journal.pmed.1004049>
- 571 30. Barocas JA, Gai MJ, Amuchi B, Jawa R, Linas BP. Impact of medications for opioid use disorder  
572 among persons hospitalized for drug use-associated skin and soft tissue infections. *Drug Alcohol  
573 Depend*. 2020;215:108207. <https://doi.org/10.1016/j.drugalcdep.2020.108207>
- 574 31. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV  
575 infection for people who inject drugs: why individual, structural, and combination approaches are  
576 needed. *Lancet*. 2010 Jul 24;376(9737):285–301. [https://doi.org/10.1016/s0140-6736\(10\)60742-  
577 8](https://doi.org/10.1016/s0140-6736(10)60742-8)
- 578 32. Perlman DC, Jordan AE. The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level  
579 Causes and Interventions. *Curr HIV/AIDS Rep*. 2018 Apr 1;15(2):96–112.  
580 <https://doi.org/10.1007/s11904-018-0390-3>
- 581 33. Collins AB, Boyd J, Cooper HLF, McNeil R. The intersectional risk environment of people who use  
582 drugs. *Soc Sci Med*. 2019 Aug 1;234:112384. <https://doi.org/10.1016/j.socscimed.2019.112384>

- 583 34. Rhodes T. The 'risk environment': a framework for understanding and reducing drug-related  
584 harm. *International Journal of Drug Policy*. 2002 Jun 1;13(2):85–94.  
585 [https://doi.org/10.1016/S0955-3959\(02\)00007-5](https://doi.org/10.1016/S0955-3959(02)00007-5)
- 586 35. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a  
587 review mapping the role of social factors. *Harm Reduct J*. 2013 May 7;10(1):7.  
588 <https://doi.org/10.1186/1477-7517-10-7>
- 589 36. Bluthenthal RN. Structural racism and violence as social determinants of health: Conceptual,  
590 methodological and intervention challenges. *Drug and Alcohol Dependence*. 2021  
591 May;222:108681. <https://doi.org/10.1016/j.drugalcdep.2021.108681>
- 592 37. Brothers TD, Lewer D, Bonn M, Webster D, Harris M. Social and structural determinants of  
593 injecting-related bacterial and fungal infections among people who inject drugs: protocol for a  
594 mixed studies systematic review. *BMJ Open*. 2021 Aug 9;11(8):e049924.  
595 <http://doi.org/10.1136/bmjopen-2021-049924>
- 596 38. Pluye P, Hong QN. Combining the Power of Stories and the Power of Numbers: Mixed Methods  
597 Research and Mixed Studies Reviews. *Annu Rev Public Health*. 2014;35(1):29–45.  
598 <https://doi.org/10.1146/annurev-publhealth-032013-182440>
- 599 39. Dekkers OM, Vandenbroucke JP, Cevallos M, Renehan AG, Altman DG, Egger M. COSMOS-E:  
600 Guidance on conducting systematic reviews and meta-analyses of observational studies of  
601 etiology. *PLOS Medicine*. 2019 Feb 21;16(2):e1002742.  
602 <https://doi.org/10.1371/journal.pmed.1002742>
- 603 40. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020  
604 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29;372:n71.  
605 <https://doi.org/10.1136/bmj.n71>
- 606 41. Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K, et al. Conducting systematic reviews of  
607 association (etiology): The Joanna Briggs Institute's approach. *JBI Evidence Implementation*. 2015  
608 Sep;13(3):163–9. <https://doi.org/10.1097/xeb.0000000000000064>
- 609 42. Lett E, Asabor E, Beltrán S, Cannon AM, Arah OA. Conceptualizing, Contextualizing, and  
610 Operationalizing Race in Quantitative Health Sciences Research. *Ann Fam Med*. 2022;20(2):157–  
611 63. <https://doi.org/10.1370/afm.2792>
- 612 43. Kaufman JS. Commentary: Causal Inference for Social Exposures. *Annual Review of Public Health*.  
613 2019;40(1):7–21. <https://doi.org/10.1146/annurev-publhealth-040218-043735>
- 614 44. Harrer M, Cuijpers P, Furukawa TA, Ebert DD. *Doing Meta-Analysis in R* [Internet]. Boca Raton, FL  
615 and London: Chapman & Hall/CRC Press; 2021.  
616 [https://bookdown.org/MathiasHarrer/Doing\\_Meta\\_Analysis\\_in\\_R/](https://bookdown.org/MathiasHarrer/Doing_Meta_Analysis_in_R/)
- 617 45. Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed Methods  
618 Appraisal Tool (MMAT) version 2018 for information professionals and researchers. *Education for*  
619 *Information*. 2018 Jan 1;34(4):285–91. [https://content.iospress.com/articles/education-for-](https://content.iospress.com/articles/education-for-information/efi180221)  
620 [information/efi180221](https://content.iospress.com/articles/education-for-information/efi180221)

- 621 46. Hong QN, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, et al. Mixed Methods Appraisal  
622 Tool (MMAT) Version 2018: User Guide [Internet]. Montreal, Canada: McGill University; 2018  
623 Aug.  
624 [http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT\\_2018\\_cri](http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf)  
625 [teria-manual\\_2018-08-01\\_ENG.pdf](http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf)
- 626 47. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials*. 1986 Sep  
627 1;7(3):177–88. [https://doi.org/10.1016/0197-2456\(86\)90046-2](https://doi.org/10.1016/0197-2456(86)90046-2)
- 628 48. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate.  
629 *Statistics in Medicine*. 2003;22(17):2693–710. <https://doi.org/10.1002/sim.1482>
- 630 49. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*.  
631 2003 Sep 4;327(7414):557–60. <https://doi.org/10.1136/bmj.327.7414.557>
- 632 50. Viechtbauer W, Cheung MWL. Outlier and influence diagnostics for meta-analysis. *Research*  
633 *Synthesis Methods*. 2010;1(2):112–25. <https://doi.org/10.1002/jrsm.11>
- 634 51. Bourgois P, Bruneau J. Needle exchange, HIV infection, and the politics of science: Confronting  
635 Canada’s cocaine injection epidemic with participant observation. *Medical Anthropology*. 2000  
636 Jan 1;18(4):325–50. <https://doi.org/10.1080/01459740.2000.9966161>
- 637 52. Bourgois P. Anthropology and epidemiology on drugs: the challenges of cross-methodological and  
638 theoretical dialogue. *International Journal of Drug Policy*. 2002 Oct 1;13(4):259–69.  
639 [https://doi.org/10.1016/S0955-3959\(02\)00115-9](https://doi.org/10.1016/S0955-3959(02)00115-9)
- 640 53. Hyshka E, Strathdee S, Wood E, Kerr T. Needle exchange and the HIV epidemic in Vancouver:  
641 Lessons learned from 15 years of research. *International Journal of Drug Policy*. 2012 Jul  
642 1;23(4):261–70. <https://doi.org/10.1016/j.drugpo.2012.03.006>
- 643 54. Roux P, Jauffret-Roustide M, Donadille C, Briand Madrid L, Denis C, Célérier I, et al. Impact of drug  
644 consumption rooms on non-fatal overdoses, abscesses and emergency department visits in  
645 people who inject drugs in France: results from the COSINUS cohort. *International Journal of*  
646 *Epidemiology*. 2023 Apr 1;52(2):562–76. <https://doi.org/10.1093/ije/dyac120>
- 647 55. Brothers TD, Lewer D, Jones N, Colledge-Frisby S, Bonn M, Wheeler A, et al. Effect of  
648 incarceration and opioid agonist treatment transitions on risk of hospitalisation with injection  
649 drug use-associated bacterial infections: A self-controlled case series in New South Wales,  
650 Australia. *International Journal of Drug Policy*. 2023 Dec 1;122:104218.  
651 <https://doi.org/10.1016/j.drugpo.2023.104218>
- 652 56. Wurcel AG, Burke D, Skeer M, Landy D, Heimer R, Wong JB, et al. Sex work, injection drug use,  
653 and abscesses: Associations in women, but not men. *Drug Alcohol Depend*. 2018 Apr 1;185:293–  
654 7.
- 655 57. Sheard L, Tompkins C. Contradictions and Misperceptions: An Exploration of Injecting Practice,  
656 Cleanliness, Risk, and Partnership in the Lives of Women Drug Users. *Qual Health Res*. 2008 Nov  
657 1;18(11):1536–47. <https://doi.org/10.1177/1049732308325838>

- 658 58. Fairbairn N, Small W, Van Borek N, Wood E, Kerr T. Social structural factors that shape assisted  
659 injecting practices among injection drug users in Vancouver, Canada: a qualitative study. *Harm*  
660 *Reduction Journal*. 2010 Aug 31;7(1):20. <https://doi.org/10.1186/1477-7517-7-20>
- 661 59. Wood E, Spittal PM, Kerr T, Small W, Tyndall MW, O'Shaughnessy MV, et al. Requiring Help  
662 Injecting as a Risk Factor for HIV Infection in the Vancouver Epidemic. *Can J Public Health*. 2003  
663 Sep;94(5):355–9. <https://doi.org/10.1007/bf03403560>
- 664 60. Collins AB, Boyd J, Czechaczek S, Hayashi K, McNeil R. (Re)shaping the self: An ethnographic study  
665 of the embodied and spatial practices of women who use drugs. *Health & Place*. 2020 May  
666 1;63:102327. <https://doi.org/10.1016/j.healthplace.2020.102327>
- 667 61. Collins AB, Boyd J, Hayashi K, Cooper HLF, Goldenberg S, McNeil R. Women's utilization of  
668 housing-based overdose prevention sites in Vancouver, Canada: An ethnographic study. *Int J*  
669 *Drug Policy*. 2020 Feb;76:102641. <https://doi.org/10.1016/j.drugpo.2019.102641>
- 670 62. Boyd J, Collins AB, Mayer S, Maher L, Kerr T, McNeil R. Gendered violence and overdose  
671 prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada.  
672 *Addiction*. 2018;113(12):2261–70. <https://doi.org/10.1111/add.14417>
- 673 63. Summers PJ, Struve IA, Wilkes MS, Rees VW. Injection-site vein loss and soft tissue abscesses  
674 associated with black tar heroin injection: A cross-sectional study of two distinct populations in  
675 USA. *Int J Drug Policy*. 2017 Jan;39:21–7. <https://doi.org/10.1016/j.drugpo.2016.08.006>
- 676 64. Ciccarone D, Unick GJ, Cohen J, Mars SG, Rosenblum D. Nationwide Increase in Hospitalizations  
677 for Heroin-related Soft Tissue Infections: Associations with Structural Market Conditions. *Drug*  
678 *Alcohol Depend*. 2016 Jun 1;163:126–33. <https://doi.org/10.1016/j.drugalcdep.2016.04.009>
- 679 65. Ciccarone D, Harris M. Fire in the vein: Heroin acidity and its proximal effect on users' health.  
680 *International Journal of Drug Policy*. 2015 Nov 1;26(11):1103–10.  
681 <https://doi.org/10.1016/j.drugpo.2015.04.009>
- 682 66. Harris M, Scott J, Wright T, Brathwaite R, Ciccarone D, Hope V. Injecting-related health harms and  
683 overuse of acidifiers among people who inject heroin and crack cocaine in London: a mixed-  
684 methods study. *Harm Reduct J*. 2019 Nov 13;16(1):60. [https://doi.org/10.1186/s12954-019-0330-](https://doi.org/10.1186/s12954-019-0330-6)  
685 6
- 686 67. Lambdin BH, Bluthenthal RN, Zibbell JE, Wenger L, Simpson K, Kral AH. Associations between  
687 perceived illicit fentanyl use and infectious disease risks among people who inject drugs. *Int J*  
688 *Drug Policy*. 2019 Dec;74:299–304. <https://doi.org/10.1016/j.drugpo.2019.10.004>
- 689 68. Kenny KS, Kolla G, Greig S, Bannerman M, Phillips D, Altenberg J, et al. Association of Illicit  
690 Fentanyl Use with Injection Risk Practices Among People who Inject Drugs. *AIDS Behav*. 2023 Jun  
691 1;27(6):1757–65. <https://doi.org/10.1007/s10461-022-03908-x>
- 692 69. Benrubi LM, Silcox J, Hughto J, Stopka TJ, Palacios WR, Shrestha S, et al. Trends and correlates of  
693 abscess history among people who inject drugs in Massachusetts: A mixed methods exploration  
694 of experiences amidst a rapidly evolving drug supply. *Drug and Alcohol Dependence Reports*.  
695 2023 Sep 1;8:100176. <https://doi.org/10.1016/j.dadr.2023.100176>

- 696 70. Lloyd M, Ransom EM, Anderson NW, Farnsworth CW. Evaluation of Infectious Disease Test  
697 Ordering and Positivity Rates in Illicit Fentanyl Users. *The Journal of Applied Laboratory Medicine*.  
698 2021 Jan 12;6(1):79–92. <https://doi.org/10.1093/jalm/jfaa194>
- 699 71. Harvey LH, Green TC, Park JN, Rich JD. Xylazine in the drug supply: A research agenda.  
700 *International Journal of Drug Policy*. 2023 Oct 1;120:104190.  
701 <https://doi.org/10.1016/j.drugpo.2023.104190>
- 702 72. Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, et al. Reducing the harms  
703 of xylazine: clinical approaches, research deficits, and public health context. *Harm Reduction*  
704 *Journal*. 2023 Sep 30;20(1):141. <https://doi.org/10.1186/s12954-023-00879-7>
- 705 73. Kenney SR, Phillips KT, Herman DS, Keosaian J, Anderson BJ, Stein MD. Perceived Behavioral  
706 Control and Barriers to Cleaning Skin Before Injecting Drugs. *Journal of Addiction Medicine*. 2020  
707 Jun;14(3):231–5. <https://doi.org/10.1097/adm.0000000000000564>
- 708 74. Kimmel SD, Phillips KT, Anderson BJ, Stein MD. Characteristics associated with motivation to stop  
709 substance use and improve skin and needle hygiene among hospitalized patients who inject  
710 drugs. *Substance Abuse*. 2022 Dec 1;43(1):878–83.  
711 <https://doi.org/10.1080/08897077.2021.2007520>
- 712 75. Varga LM, Chitwood DD, Fernandez MI. Research note: Factors associated with skin cleaning prior  
713 to injection among drug users. *J Drug Issues*. 2006;36(4):1015–30.  
714 <https://doi.org/10.1177/0022042606036004>
- 715

